NasdaqCM - Delayed Quote USD

Tiziana Life Sciences Ltd (TLSA)

0.6102 -0.0589 (-8.80%)

At close: 4:00:00 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Tiziana’s nasal foralumab reduces microglial activation in progressive MS trial

Proactive 1d ago

TLSA
-8.81%
Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab

GlobeNewswire 1d ago

TLSA
-8.81%
Tiziana Life Sciences to advance foralumab partnering talks at BIO-Europe 2026

Proactive 1d ago

TLSA
-8.81%
Tiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast

GlobeNewswire 1d ago

TLSA
-8.81%
Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results

GlobeNewswire 5d ago

TLSA
-8.81%
Tiziana Life Sciences reports positive phase 2a results for Intranasal Foralumab in MS

Proactive 8d ago

TLSA
-8.81%
Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

GlobeNewswire 8d ago

TLSA
-8.81%
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

GlobeNewswire 20d ago

TLSA
-8.81%
Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab

Proactive 25d ago

TLSA
-8.81%
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

GlobeNewswire 25d ago

TLSA
-8.81%
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy

Proactive 1mo ago

TLSA
-8.81%
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

GlobeNewswire 1mo ago

TLSA
-8.81%

Performance Overview

Return	TLSA	S&P 500 (^GSPC)
YTD	-59.05%	+9.87%
1-Year	-65.13%	+10.08%
3-Year	+3.42%	+70.34%

U.S. markets closed

Tiziana Life Sciences Ltd (TLSA)

Tiziana’s nasal foralumab reduces microglial activation in progressive MS trial

Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab

Tiziana Life Sciences to advance foralumab partnering talks at BIO-Europe 2026

Tiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast

Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results

Tiziana Life Sciences reports positive phase 2a results for Intranasal Foralumab in MS

Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)